• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23
    • OncoFAP-GlyPro-MMAE
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23
    • OncoFAP-GlyPro-MMAE
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry for Samuele Cazzamalli, Head of Chemistry at Philochem

by last | Sep 4, 2024 | 2024, Past Events, Press Releases

Dr. Samuele Cazzamalli, Head of Chemistry at Philochem, will be awarded the 2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry. 2024_EFMC_Prize_for Young_Medicinal_Chemist

Philogen to attend the TIDES Europe 2022 in Vienna, Austria (16-18 November)

by last | Nov 13, 2022 | 2022, Past Events

Philogen will attend the TIDES Europe in Vienna in November 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture entitled “Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics targeting Fibroblast...

Philogen to attend the Society for Immunotherapy of Cancer’s 37th Annual Meeting 2022 in Boston (8-12 November 2022)

by last | Nov 13, 2022 | Past Events

Philogen attends the SITC Annual Meeting in November 2022. Teresa Hemmerle, PhD, Senior Project Manager, to present an abstract entitled “Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against...

Philochem will be attending the 10th World ADC Conference in London

by last | Nov 13, 2022 | 2020, Press Releases

Philochem will be attending the 10th World ADC Conference in London (United Kingdom) from March 2 to 5, 2020 10th World ADC London Dr. Samuele Cazzamalli will give a plenary lecture on: “Small Molecule-DrugConjugates: Getting small to enhance targeting” Jacopo Millul...

Philogen’s management team held a webinar on 29 September 2022 at 16:00 CEST

by last | Sep 28, 2022 | 2022, Past Events

Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of 30 June 2022. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief...
« Older Entries

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch